| Item | Content |
|---|---|
| Rating | Cautiously Bullish |
| Target Price | HKD 53-58 (base-case fair value, 12 months) |
| Current Price | HKD 49.14 (close on 2026-10-30) |
| Margin of Safety | ~7.9% (base-case fair value floor of HKD 53 vs. current price) |
| Market Cap | HKD 24.09 billion (≈RMB 20.43 billion, at 1 CNY = 1.1791 HKD, as of 2026-11-01) |
| Time Horizon | 12 months |
| Report Date | 2026-11-01 |
MAOGEPING is the most fundamentally solid high-end domestic beauty name: 2025 revenue of RMB 5.050 billion (+30.0%) and net profit attributable to shareholders of RMB 1.204 billion (+36.7%); in the first three quarters of 2026, revenue +24%~26% and net profit +20%~22% (per the company's 2026-10-30 announcement), with growth driven by market share gains against a backdrop of just +2.83% for China's cosmetics industry overall. A gross margin above 84%, an operating cash flow/net profit ratio of 1.0~1.15, RMB 3.57 billion in net cash (17.5% of market cap), and zero interest-bearing debt form a rare "high growth + high cash conversion" combination among peers. Yet the stock has pulled back about 62% from its June 2025 high of HKD 130.6 (close of HKD 49.14 on 2026-10-30); 2026E P/E is just 14.1x, or 11.6x excluding net cash—fully in line with the median multiple of Hong Kong-listed beauty peers whose growth has already stalled. The market is paying zero growth premium for the only 20%+ growth name in this sector. Our judgment: the current price already prices in "unsustainable growth," creating a quantifiable expectation gap versus fundamentals; base-case fair value is HKD 53-58, roughly +13% above the current price. However, convergence of this gap depends on three conditions—Double 11 and annual results validating growth, stabilization of the selling expense ratio, and smooth renewal of the founder's name and likeness license (expiring 2026-12-31)—compounded by supply pressure from the family's 71.8% shareholding, making the pace of re-rating uncontrollable. Hence a rating of Cautiously Bullish rather than Bullish, with a confidence level of 0.55.
The nature of this opportunity: Not "discovering an overlooked company," but "a sector-wide valuation derating in which the market prices the only high-end domestic leader still growing 20%+ at the same multiple as peers whose growth has already broken down." Reverse DCF shows the current price of HKD 49.14 implies only ~2%~4% annual free cash flow growth over the next five years, versus the company's Q1-Q3 net profit growth of +20%~22% and a 2023-2025 net profit CAGR of 34.9%—the current price demands the company's growth rate be cut in half twice, and is less than half of sell-side consensus. The direction of the expectation gap is verifiable, but it must be acknowledged: in 2026 the Hong Kong market has been trading the entire beauty sector on "unsustainable growth" (Lin Qingxuan, despite 2025 revenue +102.5%, also commands only ~11-12x and fell ~36% during the year), meaning the discount may be a sector-level equilibrium rather than a stock-specific mispricing, with no timetable for recovery.
Primary share price driver over the next 12 months: Whether the selling expense ratio stabilizes (47.4% in 2026H1, +2.2pp YoY, per the company's 2026 interim report)—it simultaneously determines whether net profit growth can re-match revenue growth, and how much the market is willing to pay for "growth."
Verifiable expectation gap: Full-cycle Double 11 results (2026-11) and the 2026 annual report (expected late March 2027). If full-year revenue growth ≥24% and the selling expense ratio ≤47.5% (this report's assumption band, anchored to the actual 47.4% in 2026H1—per the company's interim report), then the "zero growth premium" pricing is falsified; conversely, if the expense ratio rises above 49% (assumption band) and net profit growth falls below 15%, the stock converges toward the bear-case scenario (HKD 40-44).
Evidence grade: B. All core financial data come directly from company announcements (checked line by line), but on the market expectations side there is no formal consensus data source—only paraphrases from 3-6 sell-side reports, most of which set target prices during the HKD 75-95 price peak and are being systematically revised down (Citi on 2026-08-31 cut its target price from HKD 97.9 to HKD 72.6; Everbright cut its 2026-28 earnings forecasts by 6%/10%/13%).
Negative constraints adopted by this report (after independent review): ① The two sets of color cosmetics market share figures (Euromonitor 3.7%@2024 vs. Industrial Securities International 5.4%@2025) use different denominators and cannot be directly stitched into "a 1.7pp gain in one year"; ② "70% payout ratio in 2025" is a definitional error; the actual 2025 payout ratio was ~40.7%; ③ Renewal of the founder's name and likeness license is not a neutral default event (see C5 for details); ④ There is no precedent in the Hong Kong beauty sector for convergence of a growth premium.
Key evidence:
Growth is driven by a dual engine of "offline same-store + online volume": 466 counters (132 cities) plus Tmall/Douyin direct sales give it the most balanced channel mix among peers (2025: 50.5% online / 49.5% offline); it is the only major high-growth beauty company with offline still growing above 20%. The external environment for the share thesis is international brands shrinking counters in high-end department stores, ceding scarce locations. Deceleration signals to be honestly noted: Q3 2026 single-quarter revenue growth of +22%~24%, below H1's +26.2%; skincare segment grew only +11.5% in 2026H1 (vs. +31.1% for full-year 2025); color cosmetics ASP was essentially flat in 2026H1 (157.4 vs. RMB 157.0 per unit), with growth relying almost entirely on volume and marketing spend. On Industrial Securities' consistent basis, color cosmetics share rose from ~4.2% in 2021 to 5.4% in 2025, roughly +0.3pp per year—the share uptrend is real, but its slope is far smaller than the apparent figure from stitching across bases.
Key evidence:
Reverse DCF (10% cost of equity, five-year explicit period + 3% perpetuity) solves for an implied five-year FCF growth center of ~3%—less than half of sell-side consensus (2026E +20%~24%) and far below the realized 2023-25 net profit CAGR of 34.9%. On an absolute basis, zero-growth economic profit value (EPV) is ~HKD 35.2/share, covering 72% of the current price; the market pays only ~28% for growth. This report's base case: 2027E net profit attributable to shareholders of RMB 1.68 billion × 11.5x (anchored to Hong Kong beauty peers' 2026E median of 11.6x, paying no premium for growth) + net cash, fair value ~HKD 55 (range 53-58), ~+13% vs. current; probability-weighted fair value ~HKD 55.4 (+12.6%). Counter-evidence must be stressed: Lin Qingxuan, growing at 40%+, also commands only 11-12x, indicating that the mechanism "peer median × higher growth = re-rating" has no precedent under current Hong Kong consumer risk appetite—hence this thesis carries a confidence of only 0.65. The odds distribution skews positive asymmetrically (downside scenario -14.5%, upside scenario +52.6%), but realization timing is governed by sector beta.
Key evidence:
The cash-machine nature of the business model is rare: outsourced manufacturing (ODM/OEM, top five suppliers ~53.3% of purchases), minimal capex (only RMB 187 million in 2025; 2024's RMB 616 million included a one-off RMB 492 million land purchase for the Hangzhou base), profits convert almost fully into distributable cash; estimated ROIC ~26% (2025). Payout ratio ~40% for FY2024/2025 (final dividend RMB 0.72/1.00 per share), a first interim dividend of RMB 0.62 in 2026 (37.7% of interim net profit), plus a buyback mandate of up to HKD 500 million. Two discounts to note: first, as of 2026-10-22 only 407,900 shares had been bought back (~2.8% of the mandate)—the support signal outweighs actual buying; second, a RMB 1 billion special dividend declared around the 2024 IPO (~1.5x 2023 net profit), combined with the ~40% payout ratio post-listing, means that under a structure with 71.8% family ownership, the primary beneficiary of cash is the controlling shareholder—the shareholder return policy exists, but its flow structure warrants objective scrutiny.
Key evidence:
The expense ratio rise is driven not by one-off promotional competition but by channel mix migration: online revenue share has risen from 50.5% for full-year 2025 to 54.1% in 2026H1; the +33.2% online growth was bought with +44.2% marketing spend—a scissors gap of ~18pp. Douyin traffic cost inflation is a platform behavior that no single brand can fully offset through operating discipline (Proya's +5.2pp selling expense ratio in Q1 2026 and -61% Q3 net profit is the cautionary example). Quantified sensitivity: on 2026E revenue of ~RMB 6.2 billion, every further 2pp rise in the selling expense ratio drags after-tax net profit by ~6%. Additional pressure comes from international brands' 2026 China recovery plus aggressive discounting, and from celebrity-IP competitors pushing into the high-end price band—if forced to match discounts/gifts, either gross margin or the expense ratio must give. This report assumes a 2026 expense ratio of 47.5%~48.5% (stabilizing but not declining), the largest swing factor in all earnings forecasts.
Key evidence:
These are two structural constraints that diversification cannot eliminate. First, the MAOGEPING brand contributes over 96% of revenue and is named directly after the founder, yet the license's annual fee is only HKD 2.98 million (~0.009% of 2026H1 revenue)—nearly free use, giving the founder ample motive to reprice in renewal negotiations; "renewal on original terms" cannot be treated as a neutral default. As of 2026-10-30, only two months remain before expiry with no renewal announcement—a binary event. Second, the family and concert parties hold ~71.8%, and average daily turnover is only ~0.25% of market cap, so any insider selling is a high-volatility event (intraday -16.9% at one point on the 2026-05-15 placement); the January 2026 sale plan and the May placement constitute a behavioral sample of continuous selling. In reverse: if a renewal is announced on or after 31 December 2026 at no less than existing terms (≥3 years), key-person risk is cleared, directly improving valuation constraints; if there are two consecutive quarters with no insider selling and buyback execution exceeds 50% of the mandate, supply pressure eases significantly.
| Metric | 2023FY | 2024FY | 2025FY | 2026H1 (latest) |
|---|---|---|---|---|
| Revenue (RMB 100M) | 28.86 | 38.85 | 50.50 | 32.67 |
| YoY | — | +34.6% | +30.0% | +26.2% |
| Net profit attributable to shareholders (RMB 100M) | 6.62 | 8.81 | 12.04 | 8.05 |
| YoY | — | +33.0% | +36.7% | +20.3% |
| Adjusted net profit (RMB 100M, non-HKFRS) | 6.64 | 9.24 | 12.09 | 8.15 |
| Gross margin | 84.8% | 84.4% | 84.2% | 84.8% |
| Net margin | 22.9% | 22.7% | 23.8% | 24.7% |
| Operating cash flow (RMB 100M) | 7.00 | 9.69 | 11.99 | 9.26 |
| Free cash flow (RMB 100M, OCF−capex) | 6.26 | 3.53* | 10.12 | 7.78 |
| Cash + cash-like assets (RMB 100M, period end) | — | — | 34.36 | 35.70** |
| Interest-bearing debt (RMB 100M, period end) | — | 3.20 | 0 | 0 |
| Debt-to-asset ratio | — | — | 15.6% | 16.5% |
| Number of counters (period end) | — | 409 | 445 | 466 |
| Registered members (10K) | — | — | 2,200+ | 2,608 (online 1,864 + offline 744) |
* 2024 free cash flow was dragged down by the one-off RMB 492 million land purchase for the Hangzhou base; ~RMB 840 million excluding it. ** Cash and cash equivalents 27.81 + time deposits 7.89 (as of 2026-06-30, interim report basis; a further RMB 89 million of wealth-management products not included). Zero interest-bearing debt, hence no net debt/EBITDA shown (net cash position).
Reasons for metric changes (items with YoY ≥ ±20%):
On 2026-10-30, the company voluntarily disclosed quarterly operating data for the first time: In Q3 2026, both revenue and net profit grew 22%~24% YoY; for the first nine months, revenue +24%~26% and net profit +20%~22%, with overall gross margin and net margin staying stable. Three observations:
Both sell-side consensus (2026E net profit attributable of RMB 1.44~1.55 billion, corresponding to +20%~24%) and this report's estimate (central case of RMB 1.45 billion, +20.4%) fall within the announced range. The Q3 data constitutes no unexpected upside; its nature is "eliminating the risk of further downward revisions."
Business model in brief: Asset-light brand owner. Production is outsourced (ODM/OEM, top five suppliers account for 53.3% of procurement), while the company controls brand, pricing, and channels—466 primarily self-operated high-end department store counters (3,300+ beauty advisors; per-counter BA staffing 2-3x international brands) + direct operations on Tmall/Douyin/Xiaohongshu. Revenue has no subscription characteristics, but repurchase rates (33.3% in full-year 2025, 27.2% in 2026H1) and the membership system (26.08 million members, +37.3% YoY) provide a quasi-recurring demand base. Evidence of pricing power: skincare ASP rose +5.2% in 2025 while volumes still grew (units +24.6%); revenue per same counter rose from RMB 4.8 million to 5.6 million in 2025 (+17%).
Cash content of earnings test: OCF/net profit attributable for 2023-2026H1 was 1.06/1.10/1.00/1.15, and FCF/net profit attributable was 0.95/0.40 (≈0.96 excluding land purchase)/0.84/0.97—book profits convert essentially in full into disposable cash, with no receivables buildup (sales are mostly cash-and-carry direct operations). Adjusted net profit differs from reported by <2% (2026H1: RMB 815 million vs 805 million), and adjustments are only genuinely one-off items such as listing expenses and share-based awards—an unaggressive accounting approach.
Return on capital: Estimated ROIC of ~26% (2025, NOPAT/invested capital), well above any reasonable WACC estimate (8%~10%). The excess return comes from brand equity and the counter system—neither on the balance sheet (intangibles only RMB 2.7 million, 0.05% of total assets; no goodwill).
Capex quality: RMB 616 million in 2024 (including a one-off RMB 492 million Hangzhou base land purchase) → RMB 187 million in 2025 → RMB 148 million in 2026H1 (committed construction in progress of RMB 113 million remaining). The Hangzhou base is designed for annual capacity of ~15.4 million units and was originally slated to commence operations in mid-2026, initially focused on semi-finished filling and packaging—this is expansionary rather than maintenance capex; under the outsourced-manufacturing model, maintenance capex is extremely low (D&A within COGS only ~RMB 3.6 million for the half year). The company does not disclose a maintenance/expansion split; this judgment is inferred from the business model.
Moat and quality red flags: Moat = founder's 40-year makeup artist IP + scarce placement in high-end department stores + high-density BA service system (offline repurchase rate of 36.5% exceeds online). Three quality red flags: deep binding of a single brand to the founder (key-person risk, see fifth investment thesis); marketing-driven high-expense model (expense ratio 47%~48%, net margin highly sensitive to marketing ROI); supplier concentration (ODM dependence, single-point quality-control failure risk). Inventory +60.2% in 2025, unexplained, is the latest warning; it declined in 2026H1 but destocking quality needs confirmation in the annual report.
Words-vs-deeds consistency: partially delivered / pragmatic-leaning-conservative. At listing, management committed to a ~30% revenue CAGR for 2024-2026—2024 +34.6%, 2025 +30.0%, first three quarters of 2026 +24%~26%: largely delivered but with a downward slope. At the 2026 interim results briefing, management expressed "a fairly cautious attitude" toward the 30% target, with confidence only in "long-term 15%+ compound growth" (as relayed by a Citi report, 2026-08-31). Use of IPO net proceeds of HK$2.524 billion (51.1% utilized as of 2026-06-30): sales network and brand building fully utilized; overseas expansion only HK$22.3 million of 378.6 million, production/supply chain HK$28.8 million of 252.4 million, R&D HK$55.5 million of 227.1 million—channel commitments delivered quickly, asset-heavy and R&D progress lagging. No clear disclosure regarding the "mid-2026 commencement" of the Hangzhou base as of the interim report; the R&D center is completed and operational; the first Hong Kong Harbour City counter (2025-10) was delivered, but overseas revenue was only RMB 6.4 million (0.2% of total). The company provides no quantitative guidance, has no record of "missed guidance," and has voluntarily disclosed quarterly data since 2026-10-30—a marginal improvement in transparency.
Shareholder friendliness: neutral-to-positive, but cash flows skew toward the family. Dividend payout of ~40% for FY2024/2025, first interim dividend in 2026 (37.7% payout ratio), and a HK$500 million buyback mandate—a nominally complete policy. But three facts lower the score: a RMB 1.0 billion special dividend declared around the 2024 IPO (≈1.5x 2023 net profit, a typical pre-IPO dividend arrangement); buyback execution of only 2.8% as of 2026-10-22; and dividends running in parallel with insider selling (six insiders' sale plans in January 2026 + a nephew's placement of HK$625 million in May), while the primary beneficiaries of cash returns are the family holding 71.8% of shares.
Risk signals: The controlling shareholder and executives jointly announced sale plans in January 2026 (≤17.2 million shares); the founder's likeness licensing fee is only HK$2.98 million per year and expires on 2026-12-31; related-party transactions are small (procurement from Huameikangyan of RMB 30.2 million and rent of RMB 2.4 million for the half year), but there is a record of a RMB 265 million related-party bridge loan in 2024 (lent and repaid within the same year). No negative news flow around the founder in the past 90 days.
By category (2025):
| Segment | Revenue (RMB 100M) | Share | Gross Margin | 2025 YoY | 2026H1 YoY | Business Logic in One Sentence |
|---|---|---|---|---|---|---|
| Color cosmetics (MAOGEPING-led) | 29.96 | 59.3% | 83.3% | +30.0% | +38.3% | Hero-product driven: foundation cream/cushion/powder compact each with retail sales over RMB 300 million |
| Skincare | 18.73 | 37.1% | 87.3% | +31.1% | +11.5% | Caviar/Black Gold premium lines; facial masks with annual retail sales over RMB 1 billion |
| Makeup artistry training | 1.47 | 2.9% | 64.4% | -2.8% | Deliberate volume control | Brand traffic gateway and professional endorsement, not a profit center |
| Fragrance | 0.34 | 0.7% | 78.4% | New | +46.0% | Palace Museum co-branded "闻道东方"; incubation stage |
By channel (2025): Online direct 39.7% (+36.1%, GM 84.2%) | Online distribution 10.8% (+49.7%) | Offline self-operated counters 44.5% (+24.2%, GM 87.3%) | Retailers (Sephora, etc.) + offline distribution 5.0% (GM 67.6%/78.8%, clearly below direct).
Profit contribution estimate: Color cosmetics contributed gross profit of ~RMB 2.50 billion (58.7% of total), skincare ~RMB 1.64 billion (38.4%)—the largest revenue segment, color cosmetics, is also the gross profit engine, but skincare contributes nearly 40% of gross profit with less revenue and a gross margin 4pp above color cosmetics (87.3% vs 83.3%, reflecting price-tier and category cost structure differences). This is precisely why skincare's deceleration from +31.1% to +11.5% warrants high vigilance: the second curve (also the higher-margin one) slowing will passively concentrate the growth engine on color cosmetics. Fragrance GM of 78.4% is below skincare—the new category has yet to show premium pricing. Training segment GM fell from 69.0% to 64.4% (the company deliberately tightened admissions and canceled pre-exam training fees); the impact is negligible. On channels, offline direct GM of 87.3% is significantly above online 84.2% (counter service premium) and retailers 67.6% (channel margin concession); any slowdown in offline expansion or decline in its share would dilute blended GM—2026H1 GM recovering to 84.8% indicates current structural changes are not yet a drag.
Accounting red flags:
Cross-period consistency: Inventory/revenue ratio for 2023-2025 shows a V-shaped swing of 11.9%→8.3%→10.3%, paired with "no company explanation"—the only cross-period anomaly so far. Gross margin (84.2%~84.8%), net margin (22.7%~24.7%), adjusted-vs-reported difference (<2%), and OCF/net profit (1.0~1.15) are highly stable over four years, with no sign of window dressing. Overall conclusion: based on the financials examined here, no systematic accounting manipulation detected; cross-period consistency is good; the only item requiring continued tracking is inventory.
Current market data: Closing price HK$49.14 (2026-10-30; this report uses this frozen anchor throughout); market cap HK$24.09 billion (≈RMB 20.43 billion, 1 CNY = 1.1791 HKD). PE (TTM) 15.3x (TTM net profit attributable RMB 1.339 billion); 2026E PE 14.1x (RMB 1.45 billion), 2027E 12.2x; PEG 0.69; PB 4.11x (~72% of net assets are cash, return on operating assets exceeds 100%, so PB has limited reference value). The company listed in December 2024, with less than 2 years of history—the "historical percentile" window for PE/PB (~14th percentile since listing) is too short; for reference only, not as a basis for judging cheapness. Liquidity note: average daily turnover ≈0.25% of market cap, roughly 2.5x above the 0.1% threshold—a low-float stock (free float ~28%); institutional entry/exit requires order splitting, so this report's conclusions apply with a discount for large capital.
What the market has already priced in: Reverse DCF solve—at the current price, implied FCFE growth of ~2%~4% per year over the next five years and a steady-state net margin of ~24% (i.e., zero improvement from current levels). In one sentence: the current price requires Mao Geping to decelerate to ~3% growth over the next five years (currently 20%+; sell-side expects 20%~24%; company's long-term framing 15%+), while the reality is a 2023-25 net profit CAGR of 34.9%, +20%~22% in the first three quarters, and an 84.8% gross margin with no signs of erosion. The gap is roughly fivefold, and the direction indicates excessive market pessimism; but peer pricing (Lin Qingxuan 11.6x with 40% growth, Juzi Bio 9.2x during earnings decline, Shangmei 12.5x during earnings collapse) suggests this is not an individual mispricing but Hong Kong's discounting of the entire beauty sector as "growth unsustainable"—the expectation gap is demonstrable, but the timing of convergence is unpredictable.
Three-layer value (per share, HKD): Asset value ~10.1 (net cash 8.59 + core net operating assets 1.53; book net assets of 11.95 as a reference ceiling); EPV (zero growth, 10% cost of equity) ~35.2, range 32~39 (FCFE conversion 0.90~1.15, discount rate 9.5%~10.5% sensitivity); current price of 49.14 = 72% EPV + 28% growth option. The market is not "paying only for zero growth" (a 28% growth premium persists), but that premium corresponds to the conservative scenario of "near-zero future growth"—for the sector's only 20%+ grower, the growth premium has been compressed to a sliver.
Three scenarios and odds (12 months, HKD/share):
| Scenario | Probability | Fair Range | Core Assumptions | vs Current |
|---|---|---|---|---|
| Bear | 0.30 | 40~44 (mid 42) | 2027E net profit RMB 1.55 billion (expense ratio 49%+, growth stalling to 11%), exit at 9x (peer downturn pricing) + net cash | -14.5% |
| Base | 0.50 | 53~58 (mid 55) | 2027E net profit RMB 1.68 billion (+16%), exit at 11.5x (peer median, zero growth premium) + net cash | +12.9% |
| Bull | 0.20 | 70~80 (mid 75) | 2027E net profit RMB 1.82 billion (+23%, skincare recovery + overseas/M&A landing), exit at 15x + net cash | +52.6% |
Exit multiple anchoring rationale: the base case's 11.5x is anchored to the HK-listed beauty peer 2026E median of 11.6x (Proya 10.1/Juzi 9.2/Shangmei 12.5/Lin Qingxuan 11.6), deliberately paying no growth premium—because the market currently won't pay it; the bull case's 15x is anchored to a discount on precedents of high-growth HK consumer stocks (below the company's median PE since listing of 26.6x, Lin Qingxuan's early post-listing highs, and the 38.5x under the CICC HK framework) and requires a recovery in HK consumer risk appetite. External coordinates: Citi's 2026-08-31 target of HK$72.6 (post-cut, implying +47.7% vs current) and Orient Securities' HK$65.85 (+34%) are sell-side anchors updated after the pullback, both above this report's base case—this report is more conservative; the reverse coordinate is this report's bear case (40~44), whose assumed combination of expense-ratio blowout + growth stall is more pessimistic than any public sell-side scenario. Probability-weighted fair value ≈HK$55.4, +12.6% vs current, with an asymmetrically positive odds distribution (downside -14.5% vs upside +52.6%).
Own earnings forecast (reconciliation anchor): 2026E revenue RMB 6.15~6.35 billion (central 6.24, +22%~26%), net profit attributable RMB 1.43~1.49 billion (central 1.45, +19%~24%)—anchored to the first-nine-month disclosure and H1 actuals; 2027E revenue RMB 7.2~7.5 billion (+16%~19%), net profit attributable RMB 1.66~1.73 billion (central 1.68, +15%~18%)—1%~5% below sell-side RMB 1.70~1.76 billion, leaving margin for the expense-ratio path. Against management's directional framing (long-term 15%+ compound growth), this report's 2027E assumptions are broadly consistent.
Conclusion: Undervalued. Target price HK$53-58 (base-case fair value), safety margin ~7.9% (base-case floor basis)—assess quality (best-in-class earnings quality and growth among peers) separately from price (zero growth premium): quality deserves a premium, and the current price demands no growth delivery whatsoever; but convergence of the discount requires at least two of the three conditions—"growth validation + expense-ratio stabilization + key-person renewal"—to materialize, and remains subject to HK consumer risk appetite and the family's supply cadence.
Market size: China's cosmetics market on an all-inclusive basis posted retail sales of approximately RMB 688.6 billion in 2024 (CIC citing National Bureau of Statistics figures), a 2019-2024 CAGR of 5.3%; in 2025, cosmetics retail sales by enterprises above designated size reached RMB 465.3 billion (NBS, published January 2026), up +5.1% YoY, with 2026Q1 at +5.9% (March alone +8.3%) — the market has shifted from the negative/marginal growth of 2022-2024 into a mild recovery. Structural segmentation is where this company actually competes: the premium beauty market was approximately RMB 209.5 billion in 2023 (Euromonitor), with a 2009-2023 CAGR of 14.5%, projected at a 2023-2028 CAGR of 6.3% (to RMB 284.7 billion) — a long-term growth rate roughly 1.2x to 2.7x that of the overall market; the color cosmetics market was approximately RMB 64.1 billion in 2025 and skincare approximately RMB 275.2 billion (Industrial Securities International citing Euromonitor; note that a separate "color cosmetics + skincare + fragrance, all categories" figure of RMB 175.2 billion is also circulating — the two denominators must not be mixed). Forward-looking forecasts: CIC projects a 2024-2029 full-market CAGR of 7.2% (skincare 8.6% / fragrance 9.3% / color cosmetics 3.8%). Per capita color cosmetics spending was USD 6.18 (2023, Euromonitor) vs Japan USD 33.86 / South Korea USD 46.4 / US USD 61.95 — penetration headroom remains the long-term narrative.
Structural evidence of domestic-brand substitution: Online domestic beauty GMV was RMB 268.86 billion in 2025, a 57.37% share (Qianyan/Yuxi Consulting online basis); domestic brands' share among TOP20 color cosmetics brands rose from 22% in 2014 to 26% in 2023 (Euromonitor); more than 60 foreign brands exited China in 2024-2025, with KOSÉ and Shiseido closing stores and rumors of Benefit's withdrawal — scarce counters vacated by premium department store withdrawals are being taken over by premium domestic brands (MAOGEPING added a net 36 counters in 2025, to 445). But the 2026 counter-signals must be presented side by side: international majors recovering in China (Estée Lauder mainland +11.8% for the first half of its fiscal year, share gains for five consecutive quarters), and Double 11's aggressive "buy one get multiple free, up to RMB 1,000 off" discounts reclaiming premium mindshare — domestic substitution is a trend, not a one-way street.
Value chain and profit distribution: Upstream ingredients and OEM/ODM manufacturing (Cosmax, Intercos, Nox Bellcow, etc.) face overcapacity — Intercos posted 2025 revenue of EUR 1.047 billion (-1.7%) with adjusted EBITDA margin of only 14.9%, leaving brands with strong bargaining power over contract manufacturers; brand owners are the most profitable link in the value chain (MAOGEPING gross margin 84.2% vs contract manufacturers' EBITDA margin 14.9%), with margin retention logic = premium pricing (benchmarked against top international price bands) − outsourced production costs (asset-light). Downstream channel bargaining power is bifurcated — in premium department stores, MAOGEPING is "the scarce brand being fought over" after foreign-brand withdrawals (malls actively recruit it), retaining strong pricing power over consumers (skincare rising in both volume and price, offline repurchase rate 36.5%); but on online platforms (Douyin/Tmall), rising traffic costs are the main driver of industry-wide SG&A ratio increases, and brands' bargaining power over platforms is generally weak and weakening.
Supply-demand and competitive landscape: Severe oversupply on the supply side — 5,000+ licensed manufacturers, over 90% of products outsourced; in Guangdong, 100 manufacturers voluntarily surrendered their production licenses in 2024, and small/mid-tier brands are exiting at an accelerating pace (top-tier brand registrations turned down in 2025). On the demand side, sharp divergence amid marginal growth: premium domestic brands (MAOGEPING +30% in 2025, Lin Qingxuan +102.5%) and international premium (Estée Lauder mainland +11.8%) are both strong, while mass-market traffic-driven domestic brands (Proya -1.7% in 2025, Bloomage -21.8%, Shangmei -8.6% in 2026H1, Giant Biogene -0.4%) are under pressure. Concentration: China color cosmetics CR10 is only 38.6% and declining year by year (Euromonitor) — highly fragmented; the premium beauty sub-market is dominated by international majors; by 2023 retail sales, MAOGEPING is the only Chinese company among the top ten premium beauty groups (1.8% share, No. 7, per Frost & Sullivan). Entry barriers: brand equity (decades of professional accumulation), scarcity of premium department store counters, self-built BA service systems, 12-16 month special-cosmetics registration cycles, and the capital threshold of sustained heavy marketing spend (industry SG&A ratio around 50%).
Cycle and regulation: The industry is in a "bottoming-out mild recovery + sharp structural divergence" phase. Leading indicators: NBS monthly cosmetics retail sales (2026Q1 +5.9%), promo GMV (2025 618: RMB 65.9 billion across four platforms, +10%; 2026Q1 color cosmetics GMV +19% vs skincare +1%), contract manufacturer orders (Cosmax China +10.2%; Intercos December 2025 single-month orders at record highs), Douyin beauty growth (26% → 14%, a sign of fading incremental dividend). Regulation (Cosmetics Supervision and Administration Regulation effective 2021, mandatory efficacy-claim evaluation, 2025 Document No. 18 deepening registration reform) is neutral-to-positive for leaders: compliance costs clear out smaller brands, and the "file-and-review" fast track for new efficacy claims benefits premium new-product iteration — MAOGEPING's fragrance/new-category expansion and overseas push benefit directly; the cost is its R&D weakness (spend ratio <1% vs industry 0.8%~4.4%), a long-term disadvantage in the "R&D arms race."
Peer benchmarking (FY2025 + latest periods):
| Company | Revenue (RMB 100M) | 2025 Growth | Latest 2026 Period Growth | Gross Margin | Net Margin (Attributable) | Key Differences vs MAOGEPING |
|---|---|---|---|---|---|---|
| MAOGEPING | 50.50 | +30.0% | H1 +26.2% / 9M +24~26% | 84.2% | 23.8% | Dual premium color cosmetics + skincare lines, most balanced channels (online 50.5%) |
| Proya | 105.97 | -1.7% | 9M +7.5%, Q3 net profit -61% | 73.3% | 14.1% | Mass-market efficacy skincare, online 95.6%, core brand -10.4% |
| Botanee | 53.59 | -6.6% | 2026Q1 +17.8% | 74.5% | 9.4% | Sensitive-skin efficacy line, proactive offline contraction of -27.9% |
| Giant Biogene | 55.20 | -0.4% | 2026H1 -6.3%, net profit -20.5% | 80.3% | 34.7% | Recombinant collagen efficacy skincare, high promo dependence |
| Shangmei | 91.78 | +35.1% | 2026H1 -8.6%, net profit -79.4% | 76.4% | 12.6% | HANSU single brand at 80%, deep Douyin KOL-dependence |
| Marubi | 34.59 | +16.5% | 9M -8.8%, net profit -43.7% | 74.3% | 7.1% | Eye care + traffic buying, 59.5% expense ratio eroding profit |
| Lin Qingxuan | 24.50 | +102.5% | 2026H1 +42.6% | ~82% | 14.7% | Premium camellia skincare, the most direct comp but roughly half the size |
(Data sources: companies' FY2025 annual reports/earnings announcements and broker commentary, compiled by this report)
Company positioning within the industry: The absolute leader and scarce pick among premium domestic beauty brands. Share trend is rising, but two bases must be presented side by side: color cosmetics share — Euromonitor basis 3.7% in 2024 (No. 4 brand); Industrial Securities International basis 5.4% in 2025 (No. 1 among domestic brands) — the two bases have different denominators (Euromonitor all-inclusive color cosmetics vs Industrial Securities International's RMB 64.1 billion retail basis) and cannot be stitched into "+1.7pp in one year"; on a consistent basis, share rose from about 4.2% to 5.4% over 2021-2025 (+0.3pp per year); premium beauty group basis — 1.8% share in 2023, No. 7, the only domestic player (Frost & Sullivan); skincare share is only 0.7%, the largest growth option contested by rivals. Moat sources: founder's 40-year professional IP (brand equity that is hard to replicate) + the premium department store counter network (445 → 466 counters; per-counter BA staffing 2-3x that of international majors) + the pricing power evidenced by 84%+ gross margin. Concerns: R&D ratio <1%, formulation dependence on OEMs, and unproven long-term skincare competitiveness.
A generic financial framework misses three defining dimensions for beauty brands — hero-product economics, channel structure, and marketing efficiency — which are the true variables behind valuation divergence in this industry.
① Hero-product economics (price × repurchase × lifecycle): MAOGEPING's Luxury Caviar Mask surpassed RMB 1 billion in annual retail sales (roughly 20% of total revenue); the Luminous Silk Setting Powder, primer, and caviar cushion each exceeded RMB 300 million, with the black cream at RMB 300M+ — per GF Securities estimates, the top five hero products account for over 70% of revenue and the top ten nearly 90%; within skincare, the caviar mask plus black cream together account for roughly 95% of skincare revenue. This is far above normal peer concentration (Proya's Ruby/Dynamik lines are multi-SKU matrices). It cuts both ways: hero products anchor mindshare and repurchase (2026H1: cushion/powder retail sales exceeded RMB 200M/300M respectively; new "primer pink" surpassed RMB 100M within six months), but the decay slope of a single product's lifecycle is steep — Florasis (loose-powder hero + fading traffic) and Perfect Diary (color cosmetics hero-product model) are industry cautionary tales. Tracking anchors: hero-product rankings during major promos, effective discount rates on core SKUs, and whether second-tier products can reach RMB 300 million in annualized revenue.
② Channel structure (offline experience vs online traffic): Online already accounts for 65%+ of China's beauty sales; Douyin's 2025 GMV of RMB 235~270 billion overtook Alibaba/Taobao-Tmall (RMB 159.8 billion) as the No. 1 online channel, but growth has slowed from 26% to about 14%. Offline is contracting industry-wide (Proya offline -12%, Botanee -27.9%) — "only premium experiential formats survive offline" — MAOGEPING's offline +24.5% (2025) is the industry's scarcest data point, and its 87.3% offline direct-store gross margin plus BA service system form an experiential moat online brands cannot replicate. The cost is structural tension: online growth (+33.2%) persistently outpaces offline (+19.9%), with online share already at 54.1% (2026H1); further online shift means long-term expense-ratio pressure — "channel balance" is a transitional state, not a steady state; "balance dividend" and "online expense ratio" cannot both improve for long.
③ Marketing efficiency (SG&A ratio × ROI): 2025 SG&A ratio comparison — Marubi 59.5% > Botanee 49.9% ≈ Proya 49.6% > MAOGEPING 48.3% (-0.7pp YoY): mass-market lines actually pay higher rates for traffic buying, while MAOGEPING achieves "high gross margin (84.2%) — mid expense ratio — high net margin (23.8%)" via natural offline counter traffic + restrained paid traffic, putting its net margin in the top tier of domestic beauty. But 2026H1's expense ratio +2.2pp to 47.4% (per the company's 2026 interim report; marketing spend +44.2%) broke three consecutive years of decline/stability — the marginal change in marketing ROI is the core point of market pricing disagreement and the core of this report's fourth investment thesis. Membership assets cushion marketing efficiency: 26.08 million members (+37.3%), repurchase rate 27.2% in 2026H1 (+0.4pp), offline repurchase 30.6% — an owned traffic pool reduces marginal dependence on paid public-domain traffic.
Rating: Cautiously bullish, confidence 0.55, time horizon 12 months. Overall judgment: quality is the best in the HK-listed beauty segment (the only one with 20%+ growth + 84%+ gross margin + 24% net margin + net cash at 17.5% of market cap + OCF/net profit of about 1.1); the price already assumes unsustainable growth (2026E PE of 14.1x, 11.6x ex-cash — on par with stagnant peers, implying about 3% five-year growth); baseline fair value HKD 53-58, probability-weighted HKD 55.4 (+12.6%), with asymmetric odds skewed positive. The reason confidence is only 0.55: convergence of the expectation gap is not fully within the company's control — it requires HK consumer risk appetite to cooperate, and the founder's likeness-rights license expiring on December 31, 2026 creates a binary event window; any stake sale by the family holding 71.8% would be an immediate shock. Strategically, the current price suits phased observation/base positions; position management must leave room to add in the bear-case scenario (HKD 40-44, -14.5%), rather than a one-time full-position bet on valuation re-rating.
Key verification checkpoints over the next 12 months:
Risk and catalyst alerts (formal summary):
All valuation and odds calculations in this report are based on a frozen anchor of HKD 49.14, the closing price on 2026-10-30; after significant price movement, all conclusions must be recalibrated.
Report data sources: MAOGEPING FY2024/FY2025 annual reports, 2026 interim report, 2026 Q3 operational announcement, and prospectus (HKEXnews); National Bureau of Statistics, Euromonitor, CIC, Frost & Sullivan, Qianyan/Yuxi Consulting (industry data, as cited via broker reports); sell-side research from Orient Securities, Citi, Everbright Securities, Industrial Securities, GF Securities, Huaxi Securities, etc. (consensus and peer forecasts); and public coverage from Sina Finance, Tencent News, ETnet, 21 Finance. FX conversion as of 2026-11-01 (1 CNY = 1.1791 HKD).